[吸入糖皮质激素治疗稳定期慢性阻塞性肺疾病患者的肺炎风险]
[Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients].
作者信息
Ruiz García Vicente, Compte Torrero Luis
机构信息
Unidad de Hospitalización a Domicilio, CASP, Hospital Universitario La Fe, Valencia, España.
出版信息
Med Clin (Barc). 2011 Sep 17;137(7):302-4. doi: 10.1016/j.medcli.2010.10.026. Epub 2011 Mar 10.
BACKGROUND AND OBJECTIVE
Treatment with inhaled steroids is related to pneumonia and acute respiratory infection. The aim of this review is to quantify the effect inhaled steroids in pneumonia in stable chronic obstructive pulmonary disease (COPD) patients.
MATERIAL AND METHOD
We performed a systematic review of the systematic reviews that have studied inhaled corticosteroids in stable COPD patients.
RESULTS
Inhaled steroid therapy in patients with clinically stable COPD causes an increase in the number of pneumonia. The NNTH of the analysed systematic reviews ranged from 12 subjects exposed to more than three years, to 80 subjects with one year follow up. Budesonide did not show this side effect.
CONCLUSION
It would be advisable to inform patients about the risk/benefit of these therapies.
背景与目的
吸入性类固醇治疗与肺炎及急性呼吸道感染有关。本综述的目的是量化吸入性类固醇对稳定期慢性阻塞性肺疾病（COPD）患者肺炎的影响。
材料与方法
我们对研究稳定期COPD患者吸入性皮质类固醇的系统评价进行了系统综述。
结果
临床稳定的COPD患者接受吸入性类固醇治疗会导致肺炎病例数增加。所分析的系统评价的需治疗人数（NNTH）范围为：暴露超过三年的12名受试者至随访一年的80名受试者。布地奈德未显示出这种副作用。
结论
建议告知患者这些治疗的风险/益处。
Zotero 插件